Catapult Therapeutics to present new CAP-100 data at the upcoming American Association for Cancer Research annual meeting

Lelystad, The Netherlands, 25 January 2019 – Catapult Therapeutics B.V., a preclinical-stage biopharmaceutical company developing cancer treatments, announced today that they will be presenting a poster on their novel anti-CCR7 antibody CAP-100 at the American Association for Cancer Research annual meeting, which will take place from March 29 to April 3, 2019 in Atlanta, Georgia.

At the meeting, a poster entitled “CAP-100: first-in-class antibody for chronic lymphocytic leukemia” will be presented by Dr Carlos Cuesta-Mateos (head of preclinical research for Catapult Therapeutics) during the session “Targeted Therapies and Immunological/Tumor Microenvironment Effects” on Wednesday April 3, 2019 (poster number :4879, Cuesta-Mateos et al).

“These preclinical results show the therapeutic potential of our first-in-class approach, which targets the inhibition of CCR7”, commented Dr Wim Mol, CEO of Catapult Therapeutics. “Preclinical models have shown that our anti-CCR7 monoclonal antibody has unique mechanisms of action and monotherapy efficacy. These findings suggest we can develop new monotherapies as well as combination therapies with existing agents to develop chemo-free regimens that will improve treatment efficacy of hematological malignancies.”